Welcome
From one colorectal cancer patient to another
I am a molecular biologist, and I was diagnosed in my late thirties. This is where I put what the evidence actually says about what you can do alongside standard treatment: new research explained in plain language, and the book I wish someone had handed me on day one.
-
Blood test led to more potentially curative recurrence treatment
In a 584-person randomised trial after surgery for nonmetastatic colorectal cancer, surveillance guided by a blood test for tumour DNA led to curative-intent treatment in 48.1% of recurrences,…
-
Hybrid resistance training was manageable, creatine added no clear benefit
In this 27-person randomized pilot trial, 24 participants completed 10 weeks of supervised hybrid resistance training, with 91.5% average exercise dose completion and 94% supplement adherence. Creatine did…
-
Chemotherapy was linked to longer time without cancer returning
Among 566 people with stage III colorectal cancer and impaired performance status, adjuvant chemotherapy was associated with longer disease-free survival after matching, HR 0.573 (P=0.003). Oxaliplatin-containing treatment showed…
-
A screening program was linked to fewer colorectal cancer deaths
In the Basque Country of Spain, age-standardized colorectal cancer mortality fell from 32.8 to 23.1 deaths per 100,000 people between 2004 and 2024, a 29.6% decline. The fall…
-
Resistance training may blunt a biological aging signal during chemotherapy
In a randomised trial of adults receiving adjuvant chemotherapy for stage II-III colon cancer, a DNA-based aging measure called GrimAge rose by 0.29 standard deviations per six months…
-
Higher nitrite intake was linked to colorectal cancer in men
Among 82,009 Swedish adults followed from 1998 to 2022, men in the highest fifth of estimated nitrite intake had a 23% higher rate of colorectal cancer than those…
These summaries are education, not medical advice. A single new study rarely changes what you should do. Discuss anything here with your oncology team before acting on it.
Treatments being tested
Trials open to people with bowel cancer
Live records from the public trial registry, re-checked against it every day or two. Not recommendations — a starting point for a conversation with your own oncology team.
400 trials
Recruiting nowPhase 2
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Recruiting nowPhase 2
Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer
Recruiting nowPhase 2
Total Neoadjuvant Therapy in Rectal Cancer
The book behind this site
The Colorectal Cancer Blueprint
What the evidence actually supports alongside standard treatment, with every recommendation graded for evidence quality, effect size and safety.
Written by Andreas Porse, a molecular biologist who is also a colorectal cancer patient. Most people leave surgery and chemotherapy without being told that diet, exercise, supplements and a handful of common pharmacy drugs can move their recurrence risk. This book closes that gap, and is honest about where the evidence is thin.
- 31chapters
- 360+studies cited
- 60+illustrations
- 579pages, Kindle edition
Figures from the book and the complete contents are on the book page.
Keep up with the research
New colorectal cancer research, screened and explained in plain language, sent when there is something genuinely worth reading. Roughly monthly, never more than that.
One email when there is something worth reading, usually monthly. No advertising, no selling your address, unsubscribe in one click.